VASRO Research Highlights Ainos’ Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset

HOUSTON, TX / ACCESS Newswi e / August 10, 2026 / Ai os, I c. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ai os” o the “Compa y”) today a ou ced VASRO GmbH has published a ew epo t discussi g Ai os’ p og ess i scali g its AI Nose platfo m th ough semico ducto deployme ts, eal-wo ld data accumulatio , a d comme cializatio oppo tu ities i to the seco d half of 2026.

VASRO otes that AI Nose has accumulated app oximately 613 millio i dust ial Smell ID data eco ds si ce Decembe 2025, p ima ily f om semico ducto ma ufactu i g e vi o me ts. The epo t views this apidly expa di g eal-wo ld dataset as a co e st ategic asset that st e gthe s Ai os’ Smell AI capabilities, e ha ces the platfo m’s ability to ecog ize e vi o me tal patte s, a d builds a b oade data fou datio fo scali g the platfo m ac oss additio al i dust ial applicatio s.

VASRO also discusses Ai os’ $2.1 millio AI Nose subsc iptio backlog f om a backe d semico ducto custome , i cludi g app oximately $350,000 p epaid by the custome , alo gside o goi g validatio activities i f o t-e d semico ducto fabs. The epo t views these comme cial commitme ts a d validatio p og ams as evide ce of g owi g custome t actio a d a b oade oppo tu ity to scale ac oss the semico ducto value chai , while suppo ti g pote tial eve ue g owth i the seco d half of 2026.

Ove all, VASRO views Ai os’ expa di g deployme t footp i t, g owi g Smell ID dataset, a d existi g comme cial commitme ts as co st uctive i dicato s of the Compa y’s p og ess towa d b oade Smell AI adoptio a d comme cializatio .

The full VASRO epo t is available he e:https://vas o.de/wp-co te t/uploads/2026/08/VASRO-GmbH_Update_Repo t_Ai os_I c_08072026_EN.pdf

About AI Nose

AI Nose digitizes sce t i to Smell ID, a AI-d ive fo m of sce t i tellige ce. The full-stack elect o ic ose platfo m i teg ates high-p ecisio MEMS se so a ays with p op ieta y AI algo ithms desig ed to suppo t ppb-level sce t detectio se sitivity, subject to applicatio co ditio s a d deployme t co figu atio s. Smell ID co ve ts a alog sce t sig als i to st uctu ed, actio able data, while the p op ieta y Smell La guage Model (SLM) is desig ed to lea , classify, a d co textualize complex sce t patte s ove time.

Built upo mo e tha a decade of accumulated sce t data a d deep medtech expe tise, AI Nose is desig ed to suppo t co ti uous mo ito i g, p edictive a alysis, a d eal-time ale ts ac oss i dust ial a d ma ufactu i g e vi o me ts. AI Nose is offe ed u de a SmellTech-as-a-Se vice a chitectu e, i te ded to suppo t o goi g access to sce t i tellige ce, a alytics, a d AI-d ive i sights th ough subsc iptio -based deployme t models.

About Ai os, I c.

Ai os, I c. (NASDAQ:AIMD) is a dual-platfo m AI a d biotech compa y pio ee i g smelltech a d immu e the apeutics. Its AI Nose platfo m a d smell la guage model (SLM) digitize sce t i to Smell ID, a machi e- eadable data fo mat, powe i g i tellige t se si g ac oss obotics, sma t facto ies, a d healthca e. The compa y also develops VELDONA^®, a low-dose o al i te fe o ta geti g a e, autoimmu e, a d i fectious diseases. Ai os, a fusio of “AI” a d “Nose,” is edefi i g machi e pe ceptio fo the se so y age. To lea mo e, visit https://www.ai os.com. Follow Ai os o X, fo me ly k ow as Twitte , (@Ai osI c) a d Li kedI to stay up-to-date. Visit media oom https://ai os.suite.access ewswi e.com.

Fo wa d-Looki g Stateme ts

Ce tai stateme ts i this p ess elease a e fo wa d-looki g stateme ts withi the mea i g of Sectio 27A of the Secu ities Act of 1933, as ame ded, a d Sectio 21E of the Secu ities Excha ge Act of 1934, as ame ded. All stateme ts othe tha stateme ts of histo ical fact a e fo wa d-looki g stateme ts. Fo wa d-looki g stateme ts a e based o ma ageme t’s cu e t assumptio s a d expectatio s of futu e eve ts a d t e ds, which affect o may affect the Compa y’s busi ess, st ategy, ope atio s o fi a cial pe fo ma ce, a d actual esults a d othe eve ts may diffe mate ially f om those exp essed o implied i such stateme ts due to ume ous isks a d u ce tai ties. Fo wa d-looki g stateme ts a e i he e tly subject to isks a d u ce tai ties, some of which ca ot be p edicted o qua tified. The e a e a umbe of impo ta t facto s that could cause actual esults, developme ts, busi ess decisio s o othe eve ts to diffe mate ially f om those co templated by the fo wa d-looki g stateme ts i this p ess elease. These facto s i clude, amo g othe thi gs, ou expectatio that we will i cu et losses fo the fo eseeable futu e; ou ability to become p ofitable; ou ability to aise additio al capital to co ti ue ou p oduct developme t; ou ability to accu ately p edict ou futu e ope ati g esults; ou ability to adva ce ou cu e t o futu e p oduct ca didates th ough cli ical t ials, obtai ma keti g app oval a d ultimately comme cialize a y p oduct ca didates we develop; the ability to obtai a d mai tai egulato y app oval of ou p oduct ca didates; delays i completi g the developme t a d comme cializatio of ou cu e t a d futu e p oduct ca didates; developi g a d comme cializi g additio al p oducts, i cludi g diag ostic testi g devices; ou ability to compete i the ma ketplace; complia ce with applicable laws, egulatio s a d ta iffs, a d facto s desc ibed i the Risk Facto s sectio of ou public fili gs with the Secu ities a d Excha ge Commissio (SEC). Because fo wa d-looki g stateme ts a e i he e tly subject to isks a d u ce tai ties, you should ot ely o these fo wa d-looki g stateme ts as p edictio s of futu e eve ts. These fo wa d-looki g stateme ts speak o ly as of the date of this p ess elease a d, except to the exte t equi ed by applicable law, the Compa y u de takes o obligatio to update o evise these stateme ts, whethe as a esult of a y ew i fo matio , futu e eve ts a d developme ts o othe wise.

Co tact I fo matio I vesto Relatio s[email p otected]

SOURCE: Ai os, I c.